You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
HUCBC modulation of Alzheimer's-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIADESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa
SBC: NANOVIR, LLC. Topic: NIAIDDESCRIPTION (provided by applicant): The proposal seeks support for the pre-clinical development of broad spectrum compounds for treatment of human papillomavirus (HPV). HPV, the most common sexually-transmitted virus, is the cause of cervical dysplasia and cervical cancer. It has also been implicated in several other hyperproliferative diseases, such as cancers of the mouth and anus, as well as t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Chronic Disease Management System
SBC: CIELO MEDSOLUTIONS, LLC Topic: NCIDESCRIPTION (provided by applicant): Our STTR Phase II proposal is designed to develop and test Cielo New Vision, the scalable, commercial health information system envisioned as a result of our Phase I work. Health Information Technology (HIT) has been at the forefront of the nation's policy considerations as we have been completing our Phase I work and this proposal for a Phase II STTR is influe ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
SBC: MABVAX THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
User Adaptation of AAC Device Voices
SBC: BIOSPEECH INC Topic: NIDCDDESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Black Bear Parathyroid Hormone as an Anabolic Agent for Bone
SBC: PROTEOS, INC. Topic: NIDDKDESCRIPTION (provided by applicant): Project Summary/Abstract. A clinical need exists for better osteoporosis treatments since only one anabolic therapy (truncated recombinant human parathyroid hormone 1-34, teriparatide/Forteo(R)) is commercially available. Bears possess the unique ability to prevent bone loss during physical inactivity (hibernation) by maintaining balanced bone remodeling; the b ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes
SBC: Metabolic Solutions Development Company, LLC Topic: NIDDKDESCRIPTION (provided by applicant): The overall objective of our proposed research is to discover a PPARg-free thiazolidinedione (TZD) which shows antidiabetic activity in a rodent model of Type 2 diabetes and demonstrates the necessary drug-like qualities to become a clinical candidate for human therapeutics. The insulin sensitizing agents of the TZD class are conventionally thought to operate t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Dysfunction in HAART: Point of Care Tests
SBC: MITOSCIENCES, INC Topic: NIGMSDESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Low cost custom synthesis microarray
SBC: BIODISCOVERY LLC Topic: NIGMSDESCRIPTION (provided by applicant): The results of our very successful phase I project showed that using projection lithography and off the shelf oligonucleotide synthesis reagents, we could in situ synthesize high density, high quality, very low cost, custom oligonucleotide microarrays on simple open substrates such as microscope slides. We also showed that using silver staining amplification it ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Multipurpose reversible terminators
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: NHGRIDESCRIPTION (provided by applicant): This Phase 2 STTR application will allow the Foundation for Applied Molecular Evolution (FfAME) to complete its transfer of technology to Firebird Biomolecular Sciences LLC, allowing Firebird to commercialize nucleoside triphosphates where the 3'-OH groups are blocked by a 3'-ONH2 group. Triphosphates having this modification are accepted by DNA polymerases and ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health